Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

VK-2019

Small molecule · Inhibitor of Epstein-Barr nuclear antigen 1 (EBNA-1) · developed by Cullinan Therapeutics

Phase 1/2 Most advanced trial (none active)
CGEM Developer
1 Registered trials

What is VK-2019?

VK-2019 is an orally available small molecule that binds Epstein-Barr nuclear antigen 1 (EBNA-1) and inhibits its DNA binding activity. It is being studied in nasopharyngeal carcinoma, an EBV-associated malignancy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Epstein-Barr nuclear antigen 1 (EBNA-1)
Mechanism
Inhibitor of Epstein-Barr nuclear antigen 1 (EBNA-1)
Pathways
EBV episomal genome maintenance, EBV genome replication and segregation, gene transactivation
Therapy area
Oncology
Developer
Cullinan Therapeutics Inc. (CGEM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
V6WN54K07K

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03682055 Phase 1/2 Nasopharyngeal Carcinoma Terminated CGEM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Nasopharyngeal CancerNasopharyngeal Carcinoma

More from Cullinan Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEM page.

Follow CGEM, the company behind VK-2019

See CGEM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CGEM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.